Form 4: Health Catalyst Chief People Officer Sells Shares Under 10b5-1 Trading Plan

Linda Llewelyn, Chief People Officer of Health Catalyst, sold 6,442 shares of common stock at $5.7976 per share on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Linda Llewelyn, the Chief People Officer of Health Catalyst, sold 6,442 shares of the company's common stock on January 15, 2025.
• The sale was executed at a price of $5.7976 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2024.
• Following the sale, Ms. Llewelyn directly owns 92,260 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice for corporate executives to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the healthcare technology sector like Health Catalyst.
• Similar filings are regularly made by executives at companies such as Cerner (now Oracle Health) and Allscripts, reflecting routine stock transactions under pre-arranged plans.

Stakeholder Impact

• The stock sale by a company executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates

Keywords

Health Catalyst, insider trading, stock sale, Rule 10b5-1, Linda Llewelyn, HCAT, Chief People Officer